Life sciences company Lunaphore (Lausanne, Switzerland) will collaborate with the Pathology Department at Massachusetts General Hospital to create an in vitro diagnostic (IVD) to evaluate the sensitivity of solid tumors to poly-ADP ribose polymerase (PARP) inhibitors. Lunaphore’s chip technology can extract spatial proteomic and genomic data from tumors. The project will first focus on ovarian,…